Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
US5508023A · kind A · utility
40Cited by
2References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Apr 11, 1994 |
| Grant date | Apr 16, 1996 |
| Priority date | — |
| Expiry date | Apr 11, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K9/124
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
1,1,1,2,3,3,3-heptafluoropropane (HFC-227) has been identified as a highly polar propellant. Surfactants which have an elevated value (9.6 or greater) for their hydrophilic-lipophilic balance (HLB) can be used as suspending, wetting, and lubricating agents or cosolvents in metered dose inhaler (MDI) formulations pressurized with HFC-227 or propellant blends that contain HFC-227. Particularly preferred surfactants include polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan mono-oleate, polyethylene glycol 300, propoxylated polyethylene glycol, polyoxyethylene 4 lauryl ether, and diethylene glycol monoethyl ether.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.